Şunu aradınız:: baggrundsregimet (Danca - İngilizce)

randomiseringen blev stratificeret efter beregnet brug af enf i baggrundsregimet
randomisation was stratified by the intended use of enf in the br, previous use

studierne var identiske med hensyn til design bortset fra baggrundsregimet (br).
the trials were identical in design, with the exception of the background regimen (br).

i echo blev baggrundsregimet fastsat til n(t)rti- præparaterne tenofovirdisoproxilfumarat plus emtricitabin.
in echo, the br was fixed to the n(t)rtis, tenofovir disoproxil fumarate plus emtricitabine.

efter den 24 uger lange studieperiode fortsattes med baggrundsregimet for at gennemføre 18-24 måneders behandling for total multiresistent mycobacterium tuberculosis.
after the 24-week investigational period, the background regimen was continued to complete 18 to 24 months of total multi-drug resistant mycobacterium tuberculosis treatment.

stratificering: randomiseringen blev stratificeret efter beregnet brug af enf i baggrundsregimet (br), tidligere brug af darunavir og virusbelastningen ved screening.
stratification: randomisation was stratified by the intended use of enf in the br, previous use of darunavir and screening viral load.

i thrive bestod baggrundsregimet af 2 investigatorvalgte n(t)rti: tenofovirdisoproxilfumarat plus emtricitabin eller zidovudin plus lamivudin eller abacavir plus lamivudin.
in thrive, the br consisted of 2 investigator-selected n(t)rtis: tenofovir disoproxil fumarate plus emtricitabine or zidovudine plus lamivudine or abacavir plus lamivudine.

ved et virologisk svigt i prezista/ ritonavir- gruppen blev der identificeret 1 nrti ram i udvikling ved position 184, der var forbundet med nedsat følsomhed over for emtricitabin, som var inkluderet i baggrundsregimet.
in 1 virologic failure of the prezista/ritonavir group, 1 developing nrti ram at position 184 was identified, which was associated with a decreased susceptibility to emtricitabine included in the background regimen.

en stor del af patienterne i de kliniske undersøgelser fik atazanavir og/ eller tenofovir, og begge lægemidler medførte stigning i raltegravirs plasmakoncentrationer i de optimerede baggrundsregimer.
from the clinical trials, a large proportion of patients used atazanavir and / or tenofovir, both agents that result in increases in raltegravir plasma levels, in the optimised background regimens.